Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542421 | 1.00 | CYP3A4 (0.36) | CYP3A4CYP1A2CYP2D6KDM4EDRD2 | |
| SCHEMBL15292513 | 1.00 | CYP3A4 (0.36) | CYP3A4CYP1A2CYP2D6KDM4EDRD2 | |
| SCHEMBL14519155 | 0.94 | SHBG (0.35) | CYP3A4CYP1A2CYP2D6KDM4EDRD2 | |
| SCHEMBL14543763 | 0.94 | SHBG (0.35) | CYP3A4CYP1A2CYP2D6KDM4EDRD2 | |
| SCHEMBL15837587 | 0.89 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL18664106 | 0.89 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL4762401 | 0.89 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL19214879 | 0.87 | KDM4E (0.41) | CYP3A4CYP1A2CYP2D6KDM4E | |
| SCHEMBL13010704 | 0.85 | KDM4E (0.40) | CYP2D6KDM4E | |
| SCHEMBL23114345 | 0.84 | KDM4E (0.38) | CYP3A4CYP1A2CYP2D6KDM4EDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024038378-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-02-22 | — | — | WO | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-3860975-B1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | TRANSTECH PHARMA, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | AGER, APP, BACE1 | CYP3A4 4605/4885CYP1A2 4304/4885CYP2D6 4714/4885 |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | CYP3A4 3323/4885CYP1A2 3564/4885CYP2D6 2442/4885 |
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CYP3A4 1626/4885CYP1A2 658/4885CYP2D6 1364/4885 |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MYB, MYBBP1A, MYCBP | CYP3A4 3843/4885CYP1A2 3480/4885CYP2D6 4214/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CYP3A4 1993/4885CYP1A2 2396/4885CYP2D6 3464/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CYP3A4 4873/4885CYP1A2 4879/4885CYP2D6 4714/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CYP3A4 2566/4885CYP1A2 2070/4885CYP2D6 3211/4885 |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | CYP3A4 1355/4885CYP1A2 2131/4885CYP2D6 994/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | CYP3A4 2347/4885CYP1A2 703/4885CYP2D6 1324/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | CYP3A4 1993/4885CYP1A2 2396/4885CYP2D6 3464/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CYP3A4 2977/4885CYP1A2 2907/4885CYP2D6 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.